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The development of HIV drug resistance is a formidable
obstacle in the long term success of antiretroviral thera-
peutic regimens. To date, resistance has occurred against
all drugs that are in widespread use for treatment of HIV
disease. Moreover, HIV drug resistant viruses can be sexu-
ally transmitted and it is now estimated that as many as
10% of new HIV infections in Western countries may
carry at least one mutation associated with HIV drug
resistance. In some cases, newly infected individuals may
even harbour viruses that are resistant to two or even three
classes of antiretroviral drugs. Studies have shown that
mutations which are transmitted from one individual to
another may often persist over long periods of time i.e. 2–
7 years. Although many mutations may also revert to
wild-type, a danger is that they will have become perma-
nently archived in a patient's long-lived memory Tcells,
and that this may preclude future therapeutic options.
At the same time, many of the mutations associated with
HIV drug resistance may cause diminished "replicative
capacity" and, indeed, some clinical studies have shown
that at least some individuals infected with multi-drug
resistant strains may have lower viral loads over periods of
several years than do individuals infected with wild-type
strains. It is also interesting that some of the mutations
associated with HIV drug resistance may be less easily
transmitted than others or are present at diminished fre-
quency in newly infected hosts. In general, it appears as
though thymidine analogue mutations (TAMs), associ-
ated with resistance to zidovudine and stavudine, as well
as mutations associated with non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs), may be transmitted fairly
efficiently while mutations associated with resistance to
other nucleosides, e.g. 3TC, TDF (M184V and K65R), may
be transmitted much less frequently.
This subject has relevance in view of the widespread use of
co-formulated nevirapine/3TC/stavudine (TRImune) as a
first line regimen favored by the World Health Organisa-
tion (WHO) for use in many developing countries. There
is a strong possibility that resistance might develop over
time against several of the drugs in this regimen that have
low genetic barriers for resistance, meaning that only a
single point mutation in the reverse transcriptase gene
may yield significantly diminished levels of antiviral activ-
ity (3TC and NVP). Nonetheless, we should support this
WHO initiative (3 × 5) because this regimen is likely to
have the greatest impact and save millions of lives during
the next several years and, as well, will impact on rates of
HIV transmission.
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